Full Text
The Full Text of this article is available as a PDF (81.3 KB).
References
- 1.Beales J. Howard. New Uses for Old Drugs. In: Helms R. B., editor. Competitive Strategies in the Pharmaceutical Industry. Washington, D.C.: American Enterprise Institute for Public Policy Research; 1996. pp. 281–305. [Google Scholar]
- 2.Mehlman MJ. Off-label prescribing. New York, NY: interMDnet Corporation; 2005. [Google Scholar]
- 3.Crofab [package insert]. Brentwood, TN: Protherics Inc; January2006.
- 4.Acetadote [package insert]. Nashville, TN: Cumberland Pharmaceuticals; February2006.
- 5.Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labeling: Improving the safety and efficacy of pediatric therapies. JAMA. 2003;290:905–911. doi: 10.1001/jama.290.7.905. [DOI] [PubMed] [Google Scholar]
- 6.Hill P. Off license and off label prescribing in children: litigation fears for physicians. Arch Dis Child. 2005;90:i17–i18. doi: 10.1136/adc.2004.058867. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Specific requirements on content and format of labeling for human prescription drugs: revision of “pediatric use” subsection in the labeling,59 Federal Register 64240 (1994).
- 8.Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients,63 Federal Register 66631 (1998). [PubMed]
- 9.Federal Drug Administration [webpage on the Internet]. Approved active moieties to which FDA has granted pediatric exclusivity for pediatric studies under Section 505A of the Federal Food, Drug, and Cosmetic Act. Washington, D.C.: Federal Drug Administration [updated 23 March 2006; cited 9 May2006]. Available from: http://www.fda.gov/cder/pediatric/ exgrant.htm
- 10.Buckman Co. v. Plaintiffs’ Legal Comm. (98-1768) 531 U.S. 341 (2001);159 F.3d 817, reversed.
- 11.Oncology Tools: A short tour. Washington, D.C.: Food and Drug Administration; 2006. [Google Scholar]
- 12.Accreditation Council for Continuing Medical Education [webpage on the Internet]. Ask ACCME. Standards for Commercial Support, 5: Content and Format Without Commercial Bias. ACCME [updated 2004; cited 9 May2006]. Available from: http://www.accme.org/index.cfm/fa/faq.detail/category_id/ 2ae7d7bc-3bf4-47fa-9cc7-b75b6466c277.cfm.
- 13.Federal Drug Administration [webpage on the Internet]. Docket 02N-0209 — Request for comment on first amendment issues, Comment number: EC-9. Federal Drug Administration [update 28 May 2002; cited 9 May2006]. Available from: http://www.fda.gov/ohrms/dockets/98fr/02N-0209-EC-9.html.
- 14.Richardson v. Miller, No M1997-00205-COA-R3-CV, 2000 WI. 1157246 (Tenn. Ct. App. 16 Aug.2000)
- 15.American Academy of Pediatrics Committee on Drugs Uses of drugs not described in the package insert (off-label uses) Pediatrics. 2002;110:181–183. [PubMed] [Google Scholar]
- 16.Femrite v. Abbott Northwestern Hospital, 568 N.W. 2d 535, 542 (Minn. Ct. App.1997).